Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | FABP3 | P05413 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890628 | 1.00 | TSHR (0.55) | TSHRFABP5USP2ALDH1A1KMT2A | |
| SCHEMBL6890626 | 1.00 | TSHR (0.55) | TSHRFABP5USP2ALDH1A1KMT2A | |
| SCHEMBL6890624 | 1.00 | TSHR (0.55) | TSHRFABP5USP2ALDH1A1KMT2A | |
| SCHEMBL15116650 | 0.89 | TSHR (0.52) | TSHRFABP5USP2ALDH1A1KMT2A | |
| SCHEMBL613562 | 0.88 | TSHR (0.49) | TSHRUSP2ALDH1A1KMT2AMEN1 | |
| SCHEMBL20054279 | 0.87 | TSHR (0.51) | TSHRFABP5USP2ALDH1A1KMT2A | |
| SCHEMBL12330316 | 0.87 | TSHR (0.54) | TSHRFABP5USP2ALDH1A1KMT2A | |
| SCHEMBL15125206 | 0.87 | TSHR (0.51) | TSHRFABP5USP2ALDH1A1KMT2A | |
| SCHEMBL9715115 | 0.85 | MAPK1 (0.50) | TSHRUSP2MAPTMAPK1 | |
| SCHEMBL15113828 | 0.85 | TSHR (0.49) | TSHRUSP2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8952053-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2015-02-10 | — | — | US | disclosed |
| US-8952053-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2015-02-10 | — | — | US | disclosed |
| US-20130253045-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130253045-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130197030-A1 | Substituted 1,3-Dioxanes and There Uses | EVOLVA SA (CH) | 2013-08-01 | — | — | US | disclosed |
| US-20130197030-A1 | Substituted 1,3-Dioxanes and There Uses | EVOLVA SA (CH) | 2013-08-01 | — | — | US | disclosed |
| US-8486994-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8486994-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
| WO-2008089463-A2 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089462-A2 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089464-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | TSHR 267/4885FABP5 1182/4885USP2 3668/4885 |
| US-20130197030-A1 | Substituted 1,3-Dioxanes and There Uses | TBXA2R, PPARG, PPARA | TSHR 310/4885FABP5 667/4885USP2 4302/4885 |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | TSHR 321/4885FABP5 717/4885USP2 4338/4885 |
| US-20130253045-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | TSHR 267/4885FABP5 1182/4885USP2 3668/4885 |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | TSHR 267/4885FABP5 1182/4885USP2 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.